Xiao Jia Cai

Spectral MD, Inc. engages in the manufacture of medical devices. It focuses on the modernization of wound care offering DeepView a wound imaging system. The company was founded by J. Michael DiMaio and is headquartered in Dallas, TX.

AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018.

Amberstone Biosciences, Inc. is a company that aims to eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. The company is based in Laguna Hills, CA. The company's team of scientists and engineers strives to discover and develop transformative immunotherapeutics, pioneering a new wave of therapeutic breakthroughs. The company is developing first-in-class tumor microenvironment activated therapeutic (T-MATE). The company was founded in 2018 by Guikai George Wu. Guikai George Wu has been the CEO since 2018.

Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019.